• No results found

University of Groningen Quality of prescribing in chronic kidney disease and type 2 diabetes Smits, Kirsten Petronella Juliana

N/A
N/A
Protected

Academic year: 2021

Share "University of Groningen Quality of prescribing in chronic kidney disease and type 2 diabetes Smits, Kirsten Petronella Juliana"

Copied!
9
0
0

Bezig met laden.... (Bekijk nu de volledige tekst)

Hele tekst

(1)

University of Groningen

Quality of prescribing in chronic kidney disease and type 2 diabetes

Smits, Kirsten Petronella Juliana

IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below.

Document Version

Publisher's PDF, also known as Version of record

Publication date: 2018

Link to publication in University of Groningen/UMCG research database

Citation for published version (APA):

Smits, K. P. J. (2018). Quality of prescribing in chronic kidney disease and type 2 diabetes. Rijksuniversiteit Groningen.

Copyright

Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).

Take-down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

Downloaded from the University of Groningen/UMCG research database (Pure): http://www.rug.nl/research/portal. For technical reasons the number of authors shown on this cover page is limited to 10 maximum.

(2)

Quality of prescribing in

chronic kidney disease and

type 2 diabetes

(3)

The studies presented in this thesis were funded by ZonMW—the Netherlands Organisation for Health Research and Development (project numbers 836021013 and 836021007).

Printing of this thesis was partially supported by the University of Groningen, the SHARE graduate school and the University Medical Center Groningen.

ISBN: 978-94-034-0333-5 (printed version) ISBN: 978-94-034-0332-8 (digital version)

Cover design, lay-out design and printed by: Ridderprint – Ridderkerk © 2017, K.P.J. Smits

No parts of this thesis may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopying, recording or any infor-mation storage and retrieval system, without persmission of the author.

Quality of prescribing in chronic kidney

disease and type 2 diabetes

Proefschrift

ter verkrijging van de graad van doctor aan de Rijksuniversiteit Groningen

op gezag van de

rector magnificus prof. dr. E. Sterken en volgens besluit van het College voor Promoties.

De openbare verdediging zal plaatsvinden op woensdag 21 februari 2018 om 16.15 uur

door

Kirsten Petronella Juliana Smits

geboren op 17 augustus 1989 te Steinheim, Duitsland

(4)

Quality of prescribing in chronic kidney disease and type 2 diabetes

Proefschrift

ter verkrijging van de graad van doctor aan de Rijksuniversiteit Groningen

op gezag van de

rector magnificus prof. dr. E. Sterken en volgens besluit van het College voor Promoties.

De openbare verdediging zal plaatsvinden op woensdag 21 februari 2018 om 16.15 uur

door

Kirsten Petronella Juliana Smits geboren op 17 augustus 1989

te Steinheim, Duitsland

Quality of prescribing in chronic kidney

disease and type 2 diabetes

Proefschrift

ter verkrijging van de graad van doctor aan de Rijksuniversiteit Groningen

op gezag van de

rector magnificus prof. dr. E. Sterken en volgens besluit van het College voor Promoties.

De openbare verdediging zal plaatsvinden op woensdag 21 februari 2018 om 16.15 uur

door

Kirsten Petronella Juliana Smits

geboren op 17 augustus 1989 te Steinheim, Duitsland

(5)

Promotores Prof. dr. P. Denig Prof. dr. G.J. Navis Prof. dr. H.J.G. Bilo Copromotor Dr. G.A. Sidorenkov Beoordelingscommissie Prof. dr. R.T. Gansevoort Prof. dr. G. Nijpels Prof. dr. J.S. Burgers

(6)

Paranimfen Sophie van den Belt Sieta de Vries

(7)
(8)

Table of contents

Chapter 1. General introduction 9

Part I. Quality of prescribing in chronic kidney disease

Chapter 2. Process quality indicators for chronic kidney disease risk management: a systematic literature review

21 Chapter 3. Development and initial validation of prescribing quality

indicators for patients with chronic kidney disease

39 Chapter 4. Prescribing quality in secondary care patients with

different stages of chronic kidney disease: a retrospective study in the Netherlands

63

Part II. Quality of prescribing in type 2 diabetes

Chapter 5. Development and validation of prescribing quality indicators for patients with type 2 diabetes

81 Chapter 6. Prescribing quality and prediction of clinical outcomes in

patients with type 2 diabetes: a prospective cohort study

103 Chapter 7. Is guideline-adherent prescribing associated with quality

of life in patients with type 2 diabetes?

119 Chapter 8. General discussion and conclusion 135

English summary 149

Nederlandse samenvatting 161

Appendices

Appendix 1. Supplemental data chapter 2 177

Appendix 2. Supplemental data chapter 3 208

Appendix 3. Supplemental data chapter 4 213

Appendix 4. Supplemental data chapter 5 226

Appendix 5. Supplemental data chapter 6 248

Curriculum vitae 255

Dankwoord 259

(9)

Referenties

GERELATEERDE DOCUMENTEN

The selected PQIs were three indicators on current prescribing of statins and RAAS inhibitors when recommended and four PQIs on potential inappropriate

Tijdens de ontwikkeling zijn verscheidene indicatoren verworpen, zoals de volume-indicatoren over het gebruik van bloedglucose-ver- lagende middelen en de

· The percentage of patients with CrCl <60 ml/min that is non-adherent to the diabetes treatment since the patient received more than 120% or less than 80% of the

10 percentage points for the medication need and medication choice indicators and at 5 percentage points for safety indicators with outcome >5% or 1 percent- age point for

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim. Downloaded

(1B.) The percentage of patients with T2D between 18 and 55 years that reached the target level for HbA 1c (≤53 mmol/mol) with glucose lowering drugs.. 8- 5.5- 8+ 9+

Table S6.1: Definition of comorbidities, which were documented in the medical records by means of the ICPC or short text prescriptions which were manually coded in GIANTT.

Her PhD-project focused on developing and validating prescribing quality indicators to assess the quality of chronic kidney disease and diabetes type 2 care.